Display options
Cite
Hulin A, Chatelut E, Royer B, et al. Niveau de preuve du suivi thérapeutique pharmacologique du carboplatine. [Not Available]. Therapie. 2010;65(3):157-62doi: 10.2515/therapie/2010021.
Hulin, A., Chatelut, E., Royer, B., Le Guellec, C. (2010). Niveau de preuve du suivi thérapeutique pharmacologique du carboplatine. [Not Available]. Therapie, 65(3), 157-62. https://doi.org/10.2515/therapie/2010021
Hulin, Anne, et al. "Niveau de preuve du suivi thérapeutique pharmacologique du carboplatine." [Not Available]. Therapie vol. 65,3 (2010): 157-62. doi: https://doi.org/10.2515/therapie/2010021
Hulin A, Chatelut E, Royer B, Le Guellec C. Niveau de preuve du suivi thérapeutique pharmacologique du carboplatine. [Not Available]. Therapie. 2010 May-Jun;65(3):157-62. doi: 10.2515/therapie/2010021. French. PMID: 27392981.
Copy Download .nbib Format: NLM
Share it on

Therapie. 2010 May-Jun;65(3):157-62. doi: 10.2515/therapie/2010021.

[Not Available].

Therapie

[Article in French]
Anne Hulin, Etienne Chatelut, Bernard Royer, Chantal Le Guellec,

Affiliations

  1. CHU Henri Mondor, AP-HP, Université Paris XII, Créteil, France. Electronic address: [email protected].
  2. Institut Claudius-Regaud, Toulouse, France.
  3. CHU Jean Minjoz, Besançon, France.
  4. CHRU de Tours, Université François-Rabelais, Tours, France.

PMID: 27392981 DOI: 10.2515/therapie/2010021

Abstract

Carboplatin is an anticancer agent widely used in different types of cancer in adults and paediatrics patients. Carboplatin undergoes an high protein binding percentage in plasma and presents a major hematotoxicity. Some studies determined unbound and bound platin concentrations using flameless atomic absorption spectrophotometry or chromatography. These studies showed a relationship between carboplatin exposition expressed using AUC of ultrafiltrable concentrations with time and myelotoxicity. However, the relationship between carboplatin exposition and its efficacy is not yet established. The population approach using a nonlinear mixed effects model showed a low variability of drug exposition parameters. In some cases, Bayesian adaptative dosing were proposed. However, some particular populations will have to be taken into account such as intensive doses of carboplatin, children, patients with hemodialysis-dependant renal insufficiency or obese patients. Therapeutic carboplatin monitoring is today recommended measuring AUC ultrafiltrable concentrations in time and using described ajusted-modelling.

Copyright © 2010 Société Française de Pharmacologie et de Thérapeutique. Publié par Elsevier Masson SAS.

Keywords: carboplatin; carboplatine; suivi thérapeutique pharmacologique; therapeutic drug Monitoring

Publication Types